News

Achema with bioeconomy highlights
Enlarge image

BusinessGermany

Achema with bioeconomy highlights

22.06.2012 - Finale at ACHEMA: The world's biggest fair for chemical engineering, biotechnology and environmental protection delivers its final day.

Frankfurt – The fair brings together more than 180,000 participants and 3,770 exhibitors from 56 countries. Hot topics at ACHEMA 2012 are energy and resources. With BiobasedWorld, the organisers have introduced a special industrial biotechnology and biomass processing focus, mirroring how the knowledge-based bioeconomy has started to transform the chemical industry. The bioeconomy is not only a special focus amongst exhibitors, but was also covered by its own "BiobasedWorld" conference.

The importance of the subject was highlighted by a group of 30 science and industry experts from Germany presenting  the "Roadmap Biorefineries". This paper, worked out on behalf of the Federal Government , includes a SWOT analysis on the potential of available biorefinery technologies as well as fields where further research and development efforts are necessary by the year 2030.

Georg Schütte, State Secretary in the Federal Ministry for Education and Research, also introduced three strategic alliances in industrial biotechnology. In these alliances, partners from industry and research from a variety of industry branches work together to foster “biologisation” of industry and to deliver novel biobased products. The alliance "ZeroCarbon Footprint" , coordinated by energy giant RWE Power AG , will have a total volume of €46m, from which the half is financed by public money. It focuses on using carbon-rich waste streams as a basis for novel biotech products. The alliance "Functionalisation of polymers", coordinated by enzyme specialist Evocatal, will see the government und the respective industry partners investing €8m in total. The cosmetics and nutraceuticals alliance "NatLifE", coordinated by BRAIN AG, will have a total volume of €30m.

http://www.european-biotechnology-news.com/news/news/2012-02/achema-with-bioeconomy-highlights.html

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.07 CHF16.67%
  • EUROFINS SCIENTIFIC (F)283.68 EUR11.25%
  • MEDIGENE (D)9.35 EUR10.65%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.00%
  • NORDIC NANOVECTOR (N)24.40 NOK-9.29%
  • EVOTEC (D)3.33 EUR-6.20%

TOP

  • DBV Technologies (F)55.76 EUR31.0%
  • VERONA PHARMA (UK)5.20 GBP24.7%
  • MEDIGENE (D)9.35 EUR20.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NORDIC NANOVECTOR (N)24.40 NOK-30.5%
  • TRANSGENE (F)3.75 EUR-24.2%

TOP

  • ADOCIA (F)69.25 EUR398.9%
  • 4SC (D)4.88 EUR369.2%
  • WILEX (D)3.54 EUR321.4%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.20 SEK-68.1%
  • NEOVACS (F)1.13 EUR-66.9%

No liability assumed, Date: 01.07.2015